Publications by authors named "S J Scheidl"
Article Synopsis
- Pulmonary veno-occlusive disease (PVOD) has a poorer prognosis than idiopathic pulmonary arterial hypertension (PAH), with median survival of only 1 year post-diagnosis.
- Treatments for PAH have shown limited effectiveness for PVOD, with risks such as pulmonary oedema and mixed results from case reports on medication effects.
- Lung transplantation is the best long-term treatment for suitable patients, but candidates over a certain age or with certain cancers are typically excluded; a case study describes a successful 5-year sildenafil treatment for a 59-year-old patient with PVOD and multiple myeloma.
Purpose: To describe the rationale and design of the VOYAGER (NCT05476926) study, which aims to investigate the safety and effectiveness of faricimab and the Port Delivery System with ranibizumab (PDS) for neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) in clinical practice. VOYAGER also aims to understand drivers of clinical practice treatment outcomes by gaining novel insight into the intersection of treatment regimens, decisions, anatomic outcomes, and vision.
Design: Primary data collection, noninterventional, prospective, multinational, multicenter clinical practice study.
Liver transplantation (LT) was originally described by Starzl as a promising strategy to treat primary malignancies of the liver. Confronted with high recurrence rates, indications drifted towards non-oncologic liver diseases with LT finally evolving from a high-risk surgery to an almost routine surgical procedure. Continuously improving outcomes following LT and evolving oncological treatment strategies have driven renewed interest in transplant oncology.
View Article and Find Full Text PDFPrecision oncology approaches for patients with colorectal cancer (CRC) continue to lag behind other solid cancers. Functional precision oncology-a strategy that is based on perturbing primary tumor cells from cancer patients-could provide a road forward to personalize treatment. We extend this paradigm to measuring proteome activity landscapes by acquiring quantitative phosphoproteomic data from patient-derived organoids (PDOs).
View Article and Find Full Text PDF